Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Lithium & Battery Tech ETF (LIT) vs Moderna, Inc. (MRNA) Price & Performance

Global X Lithium & Battery Tech ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Global X Lithium & Battery Tech ETF vs Moderna, Inc. — how do they compare? Global X Lithium & Battery Tech ETF trades at $74.79, while Moderna, Inc. trades at $60.78 (market cap $23.88B). Which is the better fit depends on your goals.

LITMRNA
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$91.62$81.80
52-Week Low
$44.96$22.36
Market Cap
$23.88B
Enterprise Value
$20.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Lithium & Battery Tech ETF

LIT trades at $74.01, up 2.21% today, with bullish technical signals from moving averages but caution from oscillators. The stock has doubled over the past year, driven by strong momentum in electric vehicles, energy storage, and semiconductors. Recent news highlights global EV sales growth and China's ambitious 30% fleet target by 2030, supporting the lithium and battery technology theme.

Outlook remains positive given structural EV adoption trends, though overbought RSI levels suggest near-term consolidation risk. Key risks include Chinese export controls, regulatory changes, and competitive pressures. Analyst sentiment is constructive with buy ratings emphasizing long-term growth catalysts in clean energy transition.

Moderna, Inc.

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Lithium & Battery Tech ETF

LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.

Read more on LIT

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA